Bianca Rocca, MD, PhD

Bianca Rocca

Associate Professor of Pharmacology

MD PhD FESC

Catholic University School of Medicine, Rome, IT

  • OrcidID

Biography

Bianca Rocca, MD, PhD, FESC is Professor of Pharmacology at the Libera Università Mediterranea-LUM (Casamassima, Bari, Italy). 
She trained as a Postdoctoral Fellow at the University of Pennsylvania (Philadelphia, US), and as a haematologist (speciality board at the Catholic University School of Medicine, Rome, Italy).


She is a Fellow of the European Society of Cardiology (FESC), and has served as Chairperson elected of the ESC Working Group on Thrombosis. Currently, she is Chair elected of the WG-CVP (mandate 2026-2028). She has been nominated for the 2024-2026 mandate in the ESC Committee for Practice Guidelines (CPG).


She has contributed to several ESC Guidelines (2018 Guidelines on cardiovascular disease in pregnancy, 2019 and 2023 Guidelines on diabetes, 2024 Guidelines on atrial fibrillation as reviewer coordinator), and she has contributed to the 2022 EHA Guidelines on antithrombotic therapy in cancer patients with thrombocytopenia. 


She is an Honorary Member of the Romanian Society of Cardiology (2023), and has received certificates of achievement from the ESC for her commitment as Chairperson and for her outstanding contributions to ESC Guidelines. Since 2021, she is the Co-Chair of the European Certificate of Advanced Studies in Antithrombotic Management from the University of Maastricht. 


She is a member of the Editorial Board of Diabetes and Vascular Disease Research, EHJ-Cardiovascular Pharmacology, Cardiovascular Drugs and Therapy, European Journal of Preventive Cardiology, Journal of Thrombosis and Thrombolysis and International Journal of Cardiology, and is Associate Editor of European Cardiology Review.


She has co-authored over 200 publications in peer-reviewed journals with over 28,000 citations and has an h-index of 60. Her main scientific interests are antithrombotic drugs, eicosanoids, haemostasis, platelets, precision cardiovascular pharmacology and myeloproliferative neoplasms.